By NextBestFitBrand-name drug prices far above production cost
Drug prices reflect market exclusivity, not production cost. Insulin costs roughly $2–6 a vial to make, yet U.S. list prices ran to hundreds of dollars before recent caps.
Evidence
- Estimated insulin production cost about $2–6 per vial; a profitable price would be $48–133 per person per year.
- U.S. brand-name prices average 422% of other OECD countries.Sources: RAND Corporation (2024)
Who's affected
- People with unaffordable deductibles or coinsurance: Market exclusivity sustains drug prices far above production cost.
- Uninsured people: Market exclusivity sustains drug prices far above production cost.
- Health insurers, brokers, and their shareholders: Market exclusivity sustains drug prices far above production cost.
- Taxpayers and public budgets: Market exclusivity sustains drug prices far above production cost.
- Drug and device makers: Market exclusivity supports high prices and shareholder returns.
- Pharmacy benefit managers and their pharmacies: High list prices generate rebates for benefit managers.
Under your mix of paths
- Patent monopolies
- Fragmented buyers
- Rebate system
Related costs
Open questions
- Should drug prices be set by value, by cost-plus, by international reference, or by negotiation?
Caused or worsened by these paths
This problem only matters if one of these paths is chosen.
Leaving patents unchanged keeps prices high until all patents expire.
Solution paths (3)
Open a path for what it fixes, what it creates or worsens, who gains and who loses, precedents, and how it connects to other paths. See all paths as a decision tree.
One national body negotiates prices for every drug, using international prices and value assessments as benchmarks.
- +Brand-name drug prices far above production cost
- −Slower access to new drugs and technology
- −Price limits can cause shortages, launch delays, or exits
- −Central coverage decisions can feel like rationing
Cap U.S. prices at the median (or lowest) of peer countries.
- +Brand-name drug prices far above production cost
- −Depends on uncertain evidence or judgments
- −Price limits can cause shortages, launch delays, or exits
A public or nonprofit manufacturer produces generics with high prices or shortages (e.g., insulin).
- +Brand-name drug prices far above production cost
- +Drug shortages of cheap, essential generics
- −Solves only part of the problem
- −Takes years, or money up front, before it pays off
Also addressed by paths for other problems
Prizes or guaranteed purchases pay for innovation so qualifying drugs can then be sold at low prices.
Paying little for me-too drugs saves money while reserving high prices for drugs with large added benefits.
Accepting negotiation and assessment delays obtains lower prices and the largest savings on new treatments.